[Pre-exposure rabies vaccination using a new duck embryo vaccine].
An economical, highly purified and concentrated duck embryo rabies vaccine (PDEV) was investigated in relation to pre-exposure rabies prophylaxis. The vaccine was injected subcutaneously according to the then prescribed scheme for human diploid cell rabies vaccines (HDCV). Additionally, a third dose was given on day 120. Serum anti-rabies antibody levels were determined on days 0, 56, 120, und 170. On day 56 all volunteers showed an anti-rabies antibody level of at least 1.0 IU/ml, indicating that PDEV is sufficiently immunogenic to allow its use according to the pre-exposure schedules for HDCV. Some rather low titers noted on day 120 indicate that an early booster dose or a third primary immunization dose is justified, as recently recommended by the WHO.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D004341:Drug Evaluation; D004372:Ducks / Q000196:embryology; D006801:Humans; D007117:Immunization, Secondary; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000302:isolation & purification / Q000627:therapeutic use*; D011820:Rabies virus / Q000276:immunology
D000914:Antibodies, Viral; D011819:Rabies Vaccines
Präexpositionelle Tollwutschutzimpfung mit einer neuen Entenembryovakzine.